Nicholas Hooper

Dr. Nicholas Hooper

Emory University, Atlanta, Georgia, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
NHNicholas Hooper
Nicholas Hooper
AMAnuj Marathe
Anuj Marathe
NJNitin B Jain
Nitin B Jain
PJPrathap Jayaram
Prathap Jayaram
This review focuses on non-surgical treatment options for rotator cuff injuries and highlights the potential of mesenchymal stem cells (MSCs) as a potential regenerative approach. MSCs, sourced from various tissues like bone marrow and adipose tissue, exhibit promising mechanisms in vitro, influencing tendon-related gene expression and microenvironment modulation. Animal studies support this, showcasing MSCs’ ability to reduce inflammation, improve tissue remodeling, and enhance repaired tendon strength. Human trials, while varied and limited, suggest that MSCs might lower retear rates and enhance post-repair outcomes, but randomized controlled trials yield mixed results, emphasizing the necessity for standardized investigations. Ultimately, while cell-based therapies demonstrate an excellent safety profile, more rigorous clinical trials are necessary to determine their efficacy in improving patient outcomes and achieving lasting structural changes in rotator cuff injuries.

26 September 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
NHNicholas Hooper
Nicholas Hooper
JIJoseph Angelo Ierulli
Joseph Angelo Ierulli
CDChase Demarest
Chase Demarest
JPJohn Pitts
John Pitts
OOOluseun A. Olufade
Oluseun A. Olufade
CWChristopher Williams
Christopher Williams
Background/Objectives: Low back pain (LBP) remains one of the leading causes of disability globally and contributes significantly to healthcare expenditures. Discogenic LBP, a subtype stemming from intervertebral disc degeneration, often provesrefractory to conventional treatment modalities. Regenerative orthobiologic therapies, including platelet-rich plasma (PRP), platelet lysate (PL), and mesenchymal stem cells (MSCs), have emerged as promising alternatives, though long-term outcomes and safety profiles are not yet well understood. Methods: This case series reports 13 patients treated between 2015 and 2016 at an outpatient interventional pain center who received intradiscal culture-expanded MSC injections with or without additional injections to other surrounding vertebral structures. There was no control group. Inclusion required patients to have discogenic LBP with or without radiculopathy and at least six years of completed follow-up data. Outcomes were assessed using Numeric Rating Scale (NRS), Functional Rating Index (FRI), and modified Single Assessment Numeric Evaluation (SANE) scores at multiple time points up to 10 years post treatment. Results: Thirteen patients met the inclusion criteria. Significant reductions in NRS and FRI scores were observed at 6 months, 3 years, and 6 years (p < 0.01). At 6 years, the average NRS score decreased by 2.50 points, FRI by 24.14 points, and SANE showed a 60% improvement. At 10 years, among the seven patients who responded, average SANE improvement was 78.1%. No adverse events were reported. Conclusions: This study presents the longest known follow-up data for intradiscal MSC therapy for discogenic LBP, demonstrating sustained improvements in pain and function. These findings support further investigation into combination orthobiologic therapies as a viable long-term treatment option for chronic LBP.

6 February 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
NHNicholas Hooper
Nicholas Hooper
AAAhmad Alhusen
Ahmad Alhusen
HSHinnah Siddiqui
Hinnah Siddiqui
JPJohn Pitts
John Pitts
PJPrathap Jayaram
Prathap Jayaram
CWChristopher Williams
Christopher Williams
Background/Objectives: Rotator cuff tears (RCTs) are a leading cause of shoulder pain and disability. Management typically involves conservative measures, such as physical therapy and anti-inflammatory medications, or surgery for full-thickness or refractory tears. Regenerative medicine therapies, including platelet-rich plasma (PRP), platelet lysate (PL), and mesenchymal stem cells (MSCs), show promise as alternative treatment strategies, although long-term outcomes remain under investigation. Methods: This cohort included 30 patients with partial rotator cuff tears and were treated with culture-expanded MSC injections. There was no control group. Inclusion criteria included an imaging-confirmed diagnosis of partial-thickness rotator cuff tears. Outcomes were assessed at multiple time points up to 6 years. Pain and function were assessed using the Disabilities of the Arm, Shoulder, and Hand (DASH), a Numeric Rating Scale (NRS), and the modified Single Assessment Numeric Evaluation (SANE). Results: Thirty patients (37 shoulders) were included in the analysis. Significant improvements in the NRS and DASH scores were observed at 3, 6, 12, 18, and 24 months (p < 0.01). Twenty-four months post-treatment, the mean NRS and DASH decreased by 2.25 and 15.93 points, respectively, and SANE improved by 60%. At six years, among seven respondents, the mean SANE improvement was 75.54%. During this study, no significant adverse events were reported. Conclusions: This study provides the longest known follow-up of MSC therapy for partial-thickness RCTs, finding sustained pain and functional improvements. The findings support further research into MSC-based and combination regenerative therapies as a viable alternative treatment option for partial-thickness rotator cuff tears.

25 July 2024 in Cureus
Verified
Journal Article
Open access
NHNicholas Hooper
Nicholas Hooper
MDMinh Andy Doan
Minh Andy Doan
DDDerick Davis
Derick Davis
JMJames Morgan
James Morgan
This case report highlights the rehabilitation outcomes of a 24-year-old female who received inadvertent intrathecal digoxin during a routine cesarean section, leading to encephalomeningitis, vestibulocochlear neuritis, and incomplete paraplegia. Despite initial neurological deficits, the patient demonstrated significant improvement in both cognition and functional mobility during a one-month inpatient rehabilitation program, ultimately achieving ambulation with assistive devices. This case underscores the potential for rehabilitation of neurological sequela following accidental intrathecal digoxin administration.

23 October 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
PGPaulina Giacomelli
Paulina Giacomelli
BMBrendan Martin
Brendan Martin
JMJason Markle
Jason Markle
CWChristopher Williams
Christopher Williams
NHNicholas Hooper
Nicholas Hooper
JPJohn Pitts
John Pitts
Background/Objectives: Platelet-rich plasma (PRP) preparations vary widely, and most studies report concentration rather than absolute platelet dose, limiting cross-study comparison. This review provides an evidence-informed synthesis of platelet dose, concentration, and injectate volume in knee, hip, and glenohumeral osteoarthritis (OA). Methods: A PubMed-based narrative review included 26 primary studies (16 knee, nine hip, and one glenohumeral); systematic reviews provided context. Dose was classified as directly reported, calculated from measured product characteristics, nominally estimated, or assumption-dependent/unverifiable. Assumption-dependent values were excluded from numerical ranges. Randomized trials were assessed with the Cochrane Risk of Bias 2 tool. Results: Knee OA provided the strongest dose-related evidence. Reported, calculated, or aggregate study-level dose estimates ranged from approximately 2.5 to 13.7 billion platelets per injection, with findings suggesting a dose-related signal at approximately 5 billion platelets or greater. In hip OA, measured protocols associated with clinical improvement delivered approximately 6.2–7.0 billion platelets per injection. Glenohumeral evidence was limited to one trial. However, overall, the available evidence did not establish validated minimum or optimal dose thresholds. Conclusions: In knee OA, the available literature shows a dose-related signal at approximately 5 billion platelets or greater per injection, while hip studies report measured protocols around 6–7 billion platelets per injection. These findings are descriptive rather than prescriptive and do not establish clinical dosing thresholds or recommendations. Glenohumeral evidence remains insufficient for dose-specific conclusions.